MorphoSys Reaches Seventh Clinical Milestone in 2010
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Reaches Seventh Clinical Milestone in 2010
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
CTA Filing Takes Company Beyond Original Guidance of 6 Clinical Milestones in
2010
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it
has received a clinical milestone payment from Centocor Ortho Biotech Inc. in
connection with the regulatory filing of a clinical trial application for a
phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of
inflammatory and autoimmune diseases. Today's news marks the seventh clinical
milestone for MorphoSys in 2010.
"The seventh clinical milestone with partners in 2010 surpasses our original
expectations for the year of up to six such events," commented Dr. Marlies
Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks another
milestone for the HuCAL platform, clearly illustrating the success of this
technology."
MorphoSys's clinical pipeline now comprises nine partnered programs in Phase 1
and five in Phase 2 development as well as the Company's proprietary programs
MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208,
which is in a Phase 1 trial for chronic lymphocytic leukemia.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1474693/410922.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1474693]
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 49974
Anzahl Zeichen: 5454
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 438 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Reaches Seventh Clinical Milestone in 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
